Sodium Nitrite

Drug class: Antineoplastic Agents

Usage of Sodium Nitrite

Acute Cyanide Poisoning

Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening.

If clinical suspicion of cyanide poisoning is high, administer sodium nitrite and sodium thiosulfate without delay and in conjunction with appropriate airway, ventilatory, and circulatory support. Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen carrying capacity. Because of these risks, sodium nitrite and sodium thiosulfate should be used with caution in patients where the diagnosis of cyanide poisoning is uncertain.

Comprehensive treatment of acute cyanide intoxication requires support of vital functions. Administration of sodium nitrite and sodium thiosulfate should be considered adjunctive to appropriate supportive therapies. Airway, ventilatory and circulatory support, and oxygen administration should not be delayed in order to administer sodium nitrite and sodium thiosulfate. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222.

The human data supporting the use of sodium thiosulfate and sodium nitrite for cyanide poisoning consists primarily of published case reports. There are no randomized controlled clinical trials. Nearly all the human data describing the use of sodium thiosulfate report its use in conjunction with sodium nitrite. Dosing recommendations for humans have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports.

There have been no human studies to prospectively and systematically evaluate the safety of sodium thiosulfate or sodium nitrite in humans. Available human safety information is based largely on anecdotal case reports and case series of limited scope.

Relate drugs

How to use Sodium Nitrite

General

Sodium nitrite is available in the following dosage form(s) and strength(s):

Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial; also available in a kit with sodium thiosulfate injection 12.5 g/50 mL (250 mg/mL) in single-dose vials for the treatment of cyanide poisoning.

Dosage

It is essential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Pediatric Patients

Dosage and Administration

Sodium nitrite and sodium thiosulfate should be administered as early as possible after a diagnosis of acute life-threatening cyanide poisoning has been established. Both drugs are administered by slow IV injection. Sodium nitrite should be administered first, followed immediately by sodium thiosulfate. (See Table 1 for dosage recommendations.) Blood pressure must be monitored during infusion. The rate of infusion should be decreased if significant hypotension is noted.

Table 1: Dosage of Sodium Nitrite and Sodium Thiosulfate for Cyanide Poisoning in Pediatric Patients1

Population

Dosage Regimen

Children

Sodium nitrite: 0.2 mL/kg (6 mg/kg or 6-8 mL/m2 BSA) of sodium nitrite at the rate of 2.5 to 5 mL/minute not to exceed 10 mL

Sodium thiosulfate (250 mg/mL): 1 mL/kg of body weight (250 mg/kg or approximately 30-40 mL/m2 of BSA) not to exceed 50 mL total dose immediately following administration of sodium nitrite

If signs of poisoning reappear, repeat treatment using one-half the original dose of both sodium nitrite and sodium thiosulfate.

In patients with known anemia, it is recommended that the dosage of sodium nitrite should be reduced proportionately to the hemoglobin concentration.

Patients should be monitored for at least 24–48 hours after sodium thiosulfate administration for adequacy of oxygenation and perfusion and for recurrent signs and symptoms of cyanide toxicity. When possible, obtain hemoglobin/hematocrit when treatment is initiated. Measurements of oxygen saturation using standard pulse oximetry and calculated oxygen saturation values based on measured PO2 are unreliable in the presence of methemoglobinemia.

The safety of administering other cyanide antidotes simultaneously with sodium nitrite has not been established. If a decision is made to administer another cyanide antidote with sodium nitrite, these drugs should not be administered concurrently in the same IV line.

Adults

Dosage and Administration

Sodium nitrite and sodium thiosulfate should be administered as early as possible after a diagnosis of acute life-threatening cyanide poisoning has been established. Both drugs are administered by slow IV injection. Sodium nitrite should be administered first, followed immediately by sodium thiosulfate. (See Table 2 for dosage recommendations.) Blood pressure must be monitored during infusion. The rate of infusion should be decreased if significant hypotension is noted.

Table 2: Dosage of Sodium Nitrite and Sodium Thiosulfate for Cyanide Poisoning in Adults

Population

Adults

Sodium nitrite: 10 mL of sodium nitrite at the rate of 2.5 to 5 mL/minute

Sodium thiosulfate (250 mg/mL): 50 mL of sodium thiosulfate immediately following administration of sodium nitrite

If signs of poisoning reappear, repeat treatment using one-half the original dose of both sodium nitrite and sodium thiosulfate.

In patients with known anemia, it is recommended that the dosage of sodium nitrite should be reduced proportionately to the hemoglobin concentration.

Patients should be monitored for at least 24–48 hours after sodium thiosulfate administration for adequacy of oxygenation and perfusion and for recurrent signs and symptoms of cyanide toxicity. When possible, obtain hemoglobin/hematocrit when treatment is initiated. Measurements of oxygen saturation using standard pulse oximetry and calculated oxygen saturation values based on measured PO2 are unreliable in the presence of methemoglobinemia.

The safety of administering other cyanide antidotes simultaneously with sodium nitrite has not been established. If a decision is made to administer another cyanide antidote with sodium nitrite, these drugs should not be administered concurrently in the same IV line.

Warnings

Contraindications

  • None.

    • Warnings/Precautions

    Hypotension

    Sodium nitrite has been associated with severe hypotension, methemoglobinemia, and death at doses less than twice the recommended therapeutic doses. Hypotension may occur concurrently or separately. Sodium nitrite should be used to treat life-threatening cyanide poisoning. When the diagnosis of cyanide poisoning is uncertain and/or the patient is not in extremis, special consideration should be given to administration of sodium nitrite if the patient is known or suspected to have diminished oxygen or cardiovascular reserve (e.g., smoke inhalation victims, pre-existing anemia, substantial blood loss, cardiac or respiratory compromise) or to be at higher risk of developing methemoglobinemia (e.g., congenital methemoglobin reductase deficiency).

    Methemoglobinemia

    Supportive care alone may be sufficient treatment without administration of antidotes for many cases of cyanide intoxication, particularly in conscious patients without signs of severe toxicity. Monitor patients closely to ensure adequate perfusion and oxygenation during treatment with sodium nitrite. Monitor methemoglobin levels and administer oxygen during treatment with sodium nitrite whenever possible. When sodium nitrite is administered to humans, a wide range of methemoglobin concentrations occur. Methemoglobin concentrations as high as 58% have been reported after two 300-mg doses of sodium nitrite administered to an adult. Sodium nitrite should be used with caution in the presence of other drugs that may cause methemoglobinemia such as procaine and nitroprusside. Sodium nitrite should be used with caution in patients who may be particularly susceptible to injury from vasodilation and its related hemodynamic sequelae. Hemodynamics should be monitored closely during and after administration of sodium nitrite, and infusion rates should be slowed if hypotension occurs.

    Anemia

    Use sodium nitrite with caution in patients with known anemia. Patients with anemia will form more methemoglobin (as a percentage of total hemoglobin) than persons with normal red blood cell (RBC) volumes. Optimally, these patients should receive a sodium nitrite dose that is reduced in proportion to their oxygen carrying capacity.

    Smoke Inhalation Injury

    Use sodium nitrite with caution in persons with smoke inhalation injury or carbon monoxide poisoning because of the potential for worsening hypoxia due to methemoglobin formation.

    Neonates and Infants

    Neonates and infants may be more susceptible than adults and older pediatric patients to severe methemoglobinemia when sodium nitrite is administered. Follow reduced dosing guidelines in pediatric patients.

    G6PD Deficiency

    Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, consider alternative therapeutic approaches in these patients. Monitor patients with known or suspected G6PD deficiency for an acute drop in hematocrit. Exchange transfusion may be needed for patients with G6PD deficiency who receive sodium nitrite.

    Use with Other Drugs

    Use sodium nitrite with caution in the presence of concomitant antihypertensive medications, diuretics or volume depletion due to diuretics, or drugs known to increase vascular nitric oxide, such as PDE5 inhibitors.

    Specific Populations

    Pregnancy

    Cyanide readily crosses the placenta. Cyanide poisoning is a medical emergency in pregnancy, which can be fatal for the pregnant woman and fetus if left untreated. Treatment for cyanide poisoning should not be withheld because of potential concerns regarding the effects of sodium nitrite on the fetus. Therefore, if a pregnant woman has known or suspected cyanide poisoning, sodium nitrite for sequential use with sodium thiosulfate is recommended. There are no available data on sodium nitrite use in pregnant women to establish a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Cyanide readily crosses the placenta.

    There are no IV toxicology studies in animals to evaluate the effect of sodium nitrite on embryofetal development. In published animal studies, fetal mortality was reported when pregnant guinea pigs were subcutaneously administered sodium nitrite at 1.7 times the maximum recommended human dose (MRHD) of 450 mg sodium nitrite when maternal and fetal methemoglobin concentrations were at their peak. In other published studies, no evidence of malformations were reported in guinea pigs, mice, or rats; however, severe anemia, reduced growth, and increased pup mortality was reported when pregnant rats were treated with 4.7 times the MRHD of sodium nitrite via drinking water during gestation and throughout lactation.

    Sodium nitrite produces methemoglobin. Fetal hemoglobin is oxidized to methemoglobin more easily than adult hemoglobin. In addition, the fetus has lower levels of methemoglobin reductase than adults. Based on animal studies, prenatal exposure to sodium nitrite resulted in impaired neural development likely the result of prenatal hypoxia. If available, consider alternative therapy not known to be associated with methemoglobinemia.

    Lactation

    There are no data on the presence of sodium nitrite in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Cyanide is present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with sodium nitrite. There are no data to determine when breastfeeding may be safely restarted following the administration of sodium nitrite.

    Pediatric Use

    There are case reports in the medical literature of sodium nitrite in conjunction with sodium thiosulfate being administered to pediatric patients with cyanide poisoning; however, there have been no clinical studies to evaluate the safety or efficacy of sodium nitrite in the pediatric population. As for adult patients, dosing recommendations for pediatric patients have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports. Sodium nitrite must be used with caution in patients <6 months of age because they may be at higher risk of developing severe methemoglobinemia compared to older children and adults. The presence of fetal hemoglobin, which is oxidized to methemoglobin more easily than adult hemoglobin, and lower methemoglobin reductase levels compared to older children and adults may contribute to risk. Mortality attributed to sodium nitrite was reported following administration of an adult dose (300 mg IV followed by a second dose of 150 mg) to a 17-month old child.

    Geriatric Use

    Sodium nitrite is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

    Renal Impairment

    Sodium nitrite is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

    Common Adverse Effects

    Most common adverse reactions are syncope, hypotension, tachycardia, palpitations, dysrhythmia, methemoglobinemia, headache, dizziness, blurred vision, seizures, confusion, and coma.

    What other drugs will affect Sodium Nitrite

    Specific Drugs

    Formal drug interaction studies have not been conducted with sodium nitrite injection.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords